The essence of the theoretical background of antidepressant action is based on the monoamine hypothesis of depression. In the 1960s, it was noted that reserpine, a catecholamine-depleting agent, induced depression and that this effect was reversed by antidepressants. The involvement of monoamines was also supported by the observations suggesting that dopamine (DA) and norepinephrine (noradrenaline; NE) were functionally deficient in depression and elevated in mania. Similarly, Ashcroft proposed that an indoleamine, now called serotonin (5-hydroxytryptamine; 5HT) was deficient in depression, leading eventually to the development of SSRIs. It is widely believed that the chronic administration of SSRIs resulting in 5HT reuptake blockade is responsible for the downregulation of 5HT1A-receptors present on the cell bodies of serotoninergic neurons. This effect reduces negative feedback, increasing 5HT neuronal firing and hence 5HT synaptic availability. This is a proposed mechanism to explain the delay between acute administration of an antidepressant and the therapeutic effect. It is unlikely to be the full explanation and does not generalize to drugs acting in different ways on the monoamine systems. It is also increasingly recognized that the onset of improvement with antidepressants is immediate, although significant clinical benefit takes some weeks to be evident. Current theories of the mechanism of action of antidepressants emphasize effects beyond the synapse such as neurotropic effects [1].


Reuptake Inhibitor Augmentation Strategy Serotoninergic Neuron Discontinuation Syndrome Discontinuation Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Anderson IM, Reid IC (eds). Fundamentals of Clinical Psychopharmacology, 3rd edition. London: Informa UK Ltd, 2006.Google Scholar
  2. 2.
    Stahl SM. Essential Psychopharmacology. Cambridge: Cambridge University Press, 2006.Google Scholar
  3. 3.
    Shiloh R, Stryjer R, Nutt DJ (eds). Atlas of Psychiatric Pharmacotherapy, 2nd edition. London: Informa Healthcare, 2005.Google Scholar
  4. 4.
    Yildiz A, Pauler DK, Sachs GS. Rates of study completion with single versus split daily dosing of antidepressants: a meta-analysis. J Affect Disord 2004; 78:157–162.PubMedCrossRefGoogle Scholar
  5. 5.
    Yyldyz A, Sachs GS. Administration of antidepressants. Single versus split dosing: a meta-analysis. J Affect Disord 2001; 66:199–206.PubMedCrossRefGoogle Scholar
  6. 6.
    British National Formulary. London: BMJ Publishing Group Ltd and RPS Publishing, 2008.Google Scholar
  7. 7.
    Taylor D, Paton C, Kerwin R (eds). The Maudsley Prescribing Guidelines, 9th edition. London: Informa Healthcare, 2007.Google Scholar
  8. 8.
    Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57:507–533.PubMedCrossRefGoogle Scholar
  9. 9.
    Haddad P, Dursan S, Deakin W (eds). Adverse syndromes and psychiatric drugs: a clinical guide. New York: Oxford University Press, 2004.Google Scholar
  10. 10.
    Anderson I, Ferrier I, Baldwin R, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343–396.PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  1. 1.Neuroscience and Psychiatry Unit Mental Health and Neurodegeneration Research Group, School of MedicineUniversity of ManchesterManchesterUK
  2. 2.University of ManchesterManchesterUK

Personalised recommendations